Tallahassee Journal

HER2-Negative Breast Cancer Pipeline Insight, 2022 | In-depth Assessment Into the 85+ Pipeline Drugs and 85+ Key Players in the Therapeutics Landscape

 Breaking News
  • No posts were found

HER2-Negative Breast Cancer Pipeline Insight, 2022 | In-depth Assessment Into the 85+ Pipeline Drugs and 85+ Key Players in the Therapeutics Landscape

November 24
20:28 2022
HER2-Negative Breast Cancer Pipeline Insight, 2022 | In-depth Assessment Into the 85+ Pipeline Drugs and 85+ Key Players in the Therapeutics Landscape
Delveinsight Business Research LLP
Globally, more than 85+ key pharma and biotech companies are working on 85+ pipeline drugs in the HER2-Negative Breast Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

HER2-Negative Breast Cancer Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  HER2-Negative Breast Cancer Market. 

The HER2-Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

HER2-Negative Breast Cancer Pipeline Analysis

HER2-Negative Breast Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of HER2-Negative Breast Cancer and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2-Negative Breast Cancer Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the HER2-Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Delveinsight’s Report Covers Around 85+ Products Under Different Phases of Clinical Development Like – 

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the HER2-Negative Breast Cancer Therapeutic Segment:


HER2-Negative Breast Cancer Therapeutics Landscape

There are approx. 85+ key companies are developing therapies for HER2-Negative Breast Cancer. Currently, Jiangsu HengRui Medicine has its HER2-Negative Breast Cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the HER2-Negative Breast Cancer Therapeutics Market Include:

  • AstraZeneca

  • Laekna

  • Novartis

  • Jiangsu HengRui Medicine

  • Roche

  • Olema Pharmaceuticals

  • Haihe Biopharma

  • G1 Therapeutics

  • Merck

  • Chia Tai Tianqing Pharmaceutical

  • Tyme

  • Radius Pharmaceuticals

  • H3 Biomedicine

  • Eli Lilly and Company

  • Eagle Pharmaceuticals

And many others

HER2-Negative Breast Cancer Emerging Drugs Covered in the Report Include:

  • Capivasertib + Fulvestrant: AstraZeneca

  • Dalpiciclib: Jiangsu HengRui Medicine

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. HER2-Negative Breast Cancer Current Treatment Patterns

4. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. HER2-Negative Breast Cancer Late Stage Products (Phase-III)

7. HER2-Negative Breast Cancer Mid-Stage Products (Phase-II)

8. HER2-Negative Breast Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. HER2-Negative Breast Cancer Discontinued Products

13. HER2-Negative Breast Cancer Product Profiles

14. Key Companies in the HER2-Negative Breast Cancer Market

15. Key Products in the HER2-Negative Breast Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. HER2-Negative Breast Cancer Unmet Needs

18. HER2-Negative Breast Cancer Future Perspectives

19. HER2-Negative Breast Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/